Zidovudine theraphy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset

Lymphology

Volumn 30, Issue 3, 1997, Pages 128-136

  Fiala, Milan ^a,b   Swartz, J ^b   Teklehaimanot, S ^b   Kermani, V ^c   Funnye, A S ^b   Sayre, J W ^d   Gornbein, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KING DREW MEDICAL CENTER   (United States)

^c Immuno Biogene Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CD4 ANTIGEN; CD8 ANTIGEN; CLOFAZIMINE; COTRIMOXAZOLE; ETHAMBUTOL; GANCICLOVIR; PENTAMIDINE; RIFAMPICIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FUNGAL MENINGITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETINITIS; RETROSPECTIVE STUDY; SURVIVAL; T LYMPHOCYTE SUBPOPULATION; AGE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; IMMUNOLOGY; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CYTOMEGALOVIRUS RETINITIS; FEMALE; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; ZIDOVUDINE;

EID: 0030610431     PISSN: 00247766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Schechter, MT, KJ Craib, TN Le, et al: Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 3 (1989), 347-353.
2. Fernandez, CE, M Desco, MM Garcia , et al: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 4 (1990), 987-994.
3. Burcham, J, M Marmor, N Dubin, et al: CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 5 (1991), 365-372.
4. Bacchetti, P, AR Moss, JC Andrews, et al: Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine. J Acquir Immune Defic Syndr. 5 (1992), 732-736.
5. Saah, AJ, DR Hoover, Y He, et al: Multicenter AIDS Cohort Study: Factors influencing survival after AIDS: Report from the Multicenter AIDS cohort study (MACS), J Acquir Immune Defic Syndr. 7 (1994), 287-95.
6. Yarchoan, R, DJ Venzon, JM Pluda, et al. CD4+ count and risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med. 115 (1991), 184-189.
7. Hoover, DR, C Rinaldo, Y He, et al: Longterm survival without clinical AIDS after CD4+ cell counts fall below 200 x 106 /L AIDS. 9 (1995), 145-152.
8. Walker, BD, F Plata: Cytotoxic T lymphocytes against HIV. AIDS. 4 (1990), 177-184.
9. Walker, CM: Non-cytolytic control of HIV replication by CD8+ T cells. Immunology. 5 (1993), 195-201.
10. Mackewicz, CE, HW Ortega, JA Levy: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest. 87 (1991), 1462-1466.
11. Koszinowski, UH, M DelVal, MJ Reddehase: Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol. 154 (1990), 189-219.
12. Fiala, M, LA Cone, N Cohen, et al: Response of neurologic complications of AIDS to 3′-azido-3′-deoxythymidine and 9- (1,3-dihydroxy-2-propoxymethyl) guanine. I. Clinical features. Rev Infect Dis. 10 (1988), 250-256.
13. Fiala, M, LA Cone, J Sayre: Clinical benefits and recovery of delayed-type hypersensitivity in patients with AIDS-related complex treated with IMREG-1 or placebo. Int J Immunopharmacology 13 (1991), 999-1004.
14. Cox, DR, D Oakes; Analysis of Survival Data. London: Chapman & Hall. (1989), 91-111
15. Fiala M, V Kermani, J Gornbein: Role of CD8+ in late opportunistic infections of patients with AIDS. Res Immunol. 143 (1992), 903-907.
16. German AIDS Study Group: Survival of patients receiving zidovudine before or after diagnosis: results of a German multicenter study. Clinical Investigator. 72 (1994), 111-116.
17. Vella, S, M Giuliano, P Pezzotti, et al: Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA. 267 (1992), 1232-1236.
18. Phillips, AN, CA Sabin, J Elford, et al : CD8+ lymphocyte counts and serum immunoglobulin A levels in HIV infection as predictors of CD4+ lymphocyte depletion during 8 years of follow-up. AIDS. 7 (1993), 975-980.
19. Fischl, MA, DD Richman, MH Grieco, et al: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDSrelated complex : A double-blind, placebocontrolled trial. N Engl J Med. 317 (1987), 185-191.
20. Volberding, PA, SW Lagakos, MA Koch, et al: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 322 (1990), 941-949.
21. Fischl, MA, DD Richman, N Hansen, et al:The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type l (HIV) infection. Ann Intern Med. 112 (1990), 727-737.
22. Fischl, MA, DD Richman, DM Causey, et al: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA. 262 (1989), 2405-2410.
23. Fischl, MA, CB Parker, C Pettinelli, et al: A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 323 (1990), 1009-1014.
24. Klimas, NG: Clinical impact of adoptive therapy with purified CDS cells in HIV infection. Semin Hematol. 29 (1992), S40-S43.
25. Herberman, RB: Adoptive therapy with purified CDS cells in HIV infection. Semin Hematol. 29 (1992), S35-S40.
26. Torpey, D, X-L Huang, J Armstrong, et al: Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity. Clin Immunol and Immunopathol. 68 (1993), 263-272.
27. Soderberg, C, S Larsson, S Bergsedt-Lindquist, et al: Identification of blood mononuclear cells permissive of cytomegalovirus infection in vitro. Transpl Proc. 25 (1993), 1416-1418.
28. Fiala, M, WW Grody, HV Vinters: Role of cytomegalovirus in AIDS with emphasis on neurological and ophthalmological complications. In: Molecular Aspects of Human Cytomegalovirus Diseases. Frontiers of Virology. Y. Becker, G. Darai, E-S Huang (Eds.), Springer Verlag, (1993).
29. Casareale, D, M Fiala, LA Cone, et al: Cytomegalovirus enhances lysis of HIV-infected T lymphocytes. Int J Cancer. 44 (1989), 124-130.
30. De Maria, A, G Pantaleo, SM Schnittman, et al: Infection of CD8+ T lymphocytes with HIV. J Immunol. 146 (1991), 2220-2226.
31. Richman, DD, D Havlir: Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Drugs. 49S (1995), 9-16